Open Access
Revised international Chapel Hill consensus conference nomenclature of vasculitides
John Charles Jennette,Ronald Falk,Paul A. Bacon,Neil Basu,M. C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Gloria E. Hoffman,Jayne,Cgm Kallenburg,Peter Lamprecht,Carol A. Langford,Raashid Luqmani,A. Mahr,Eric L. Matteson,Peter A. Merkel,Seza Ozen,Charles D. Pusey,N Rasmussen,Andrew J. Rees,Dgi Scott,Ulrich Specks,John H. Stone,Kei Takahashi,Richard A. Watts +27 more
Reads0
Chats0
TLDR
A dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides to address vasculitide affecting the skin was prepared.Abstract:
To prepare a dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC2012) to address vasculitides affecting the skin (D‐CHCC). The goal was to standardize the names and definitions for cutaneous vasculitis.read more
Citations
More filters
Journal ArticleDOI
Syndromes of Thrombotic Microangiopathy
James N. George,Carla M. Nester +1 more
TL;DR: This review article covers the diverse pathophysiological pathways that can lead to microangiopathic hemolytic anemia and a procoagulant state with or without damage to the kidneys and other organs.
Journal ArticleDOI
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Loïc Guillevin,Christian Pagnoux,Alexandre Karras,Chahéra Khouatra,Olivier Aumaître,Pascal Cohen,François Maurier,Olivier Decaux,Jacques Ninet,P. Gobert,Thomas Quemeneur,Claire Blanchard-Delaunay,Pascal Godmer,Xavier Puéchal,Pierre-Louis Carron,Pierre-Yves Hatron,Nicolas Limal,Mohamed Hamidou,Maize Ducret,Eric Daugas,Thomas Papo,Bernard Bonnotte,Alfred Mahr,Philippe Ravaud,Luc Mouthon +24 more
TL;DR: More patients with ANCA-associated vasculitides had sustained remission at month 28 with rituximab than with azathioprine, and the frequencies of severe adverse events were similar in the two groups.
Journal ArticleDOI
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
David Jayne,Annette Bruchfeld,Lorraine Harper,Matthias Schaier,Michael Venning,Patrick B. Hamilton,Volker Burst,Franziska Grundmann,Michel Jadoul,Istvan Szombati,Vladimír Tesař,Mårten Segelmark,Antonia Potarca,Thomas J. Schall,Pirow Bekker +14 more
TL;DR: In conclusion, C5a receptor inhibition with avacopan was effective in replacing high-dose glucocorticoids in treating vasculitis.
Journal ArticleDOI
Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease
J. Charles Jennette,Ronald Falk +1 more
TL;DR: Clinical and experimental evidence supports a pathogenesis that is driven by ANCA-induced activation of neutrophils and monocytes, producing destructive necrotizing vascular and extravascular inflammation.
Journal ArticleDOI
ANCA-associated vasculitis.
A. Richard Kitching,Hans-Joachim Anders,Neil Basu,Elisabeth Brouwer,Jennifer Gordon,David Jayne,Joyce Kullman,Paul A. Lyons,Peter A. Merkel,Caroline O. S. Savage,Ulrich Specks,Renate Kain +11 more
TL;DR: The classification of AAVs and the pathogenetic mechanisms, diagnosis and treatment of these debilitating conditions are discussed and a need for targeted therapies with fewer adverse effects is needed.
References
More filters
Journal ArticleDOI
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
John Charles Jennette,Ronald Falk,P. A. Bacon,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Gary S. Hoffman,David Jayne,Cees G. M. Kallenberg,Peter Lamprecht,Carol A. Langford,Raashid Luqmani,Alfred Mahr,Eric L. Matteson,Peter A. Merkel,Peter A. Merkel,Seza Ozen,Charles D. Pusey,Niels Rasmussen,Andrew J. Rees,David G. I. Scott,Ulrich Specks,John H. Stone,Kei Takahashi,Richard A. Watts +28 more
TL;DR: 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides J. Watts; Arthritis & Rheumatism
Journal ArticleDOI
Nomenclature of systemic vasculitides. Proposal of an international consensus conference
Jc Jennette,Ronald J. Falk,K Andrassy,Pa Bacon,J Churg,J Churg,Wl Gross,Wl Gross,E. C. Hagen,Gs Hoffman,Gg Hunder,Cgm Kallenberg,Rt Mccluskey,Ra Sinico,Ra Sinico,Aj Rees,La Vanes,R Waldherr,Allan Wiik +18 more
TL;DR: The following are some of the conclusions and proposals made at the Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitis.
2012 Revised International Chapel Hill Consensus Conference Nomenclature of
John Charles Jennette,Ronald Falk,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Peter Lamprecht,Raashid Luqmani,Seza Ozen,Andrew J. Rees,Scott Dgi,Ulrich Specks,Kei Takahashi,Richard A. Watts +16 more
TL;DR: In this article, the running head is assigned to one of the following candidates:Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Ferrardo F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees
Journal ArticleDOI
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Gene G. Hunder,Gene G. Hunder,Daniel A. Bloch,Daniel A. Bloch,Beat A. Michel,Mary Betty Stevens,Mary Betty Stevens,William P. Arend,William P. Arend,Leonard H. Calabrese,Leonard H. Calabrese,Steven M. Edworthy,Steven M. Edworthy,Anthony S. Fauci,Anthony S. Fauci,Randi Y. Leavitt,J. T. Lie,J. T. Lie,Robert W. Lightfoot,Robert W. Lightfoot,Alfonse T. Masi,Alfonse T. Masi,Dennis J. McShane,Dennis J. McShane,John A. Mills,John A. Mills,Stanley L. Wallace,Stanley L. Wallace,Nathan J. Zvaifler,Nathan J. Zvaifler +29 more
TL;DR: Criteria for the classification of giant cell (temporal) arteritis were developed by comparing 214 patients who had this disease with 593 patients with other forms of vasculitis, and 2 other variables were included: scalp tenderness and claudication of the jaw or tongue or on deglutition.
Journal ArticleDOI
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis.
William P. Arend,Beat A. Michel,Daniel A. Bloch,Gene G. Hunder,Leonard H. Calabrese,Steven M. Edworthy,Anthony S. Fauci,Randi Y. Leavitt,J. T. Lie,Robert W. Lightfoot,Alfonse T. Masi,Dennis J. McShane,John A. Mills,Mary Betty Stevens,Stanley L. Wallace,Nathan J. Zvaifler +15 more
TL;DR: Criteria for the classification of Takayasu arteritis were developed by comparing 63 patients who had this disease with 744 control patients with other forms of vasculitis, and the presence of 3 or more of these 6 criteria demonstrated a sensitivity of 90.5% and a specificity of 97.0%.
Related Papers (5)
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
John Charles Jennette,Ronald Falk,P. A. Bacon,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Gary S. Hoffman,David Jayne,Cees G. M. Kallenberg,Peter Lamprecht,Carol A. Langford,Raashid Luqmani,Alfred Mahr,Eric L. Matteson,Peter A. Merkel,Peter A. Merkel,Seza Ozen,Charles D. Pusey,Niels Rasmussen,Andrew J. Rees,David G. I. Scott,Ulrich Specks,John H. Stone,Kei Takahashi,Richard A. Watts +28 more
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more